Choroidal Neovascularization, Mineralocorticoid Excess
Conditions
Keywords
central serous chorioretinopathy, age related macular degeneration, biomarker
Brief summary
The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.
Detailed description
Age-related macular degeneration (AMD) is the most frequent cause of blindness in industrialized countries. Multiple molecular pathways have been implicated in the pathogenesis of choroidal neovascularization (CNV). Currently, the treatment relies on neutralization of VEGF (Vascular Endothelial Growth Factor). However some patients have an incomplete response to anti-VEGF treatment. A recent study suggested the implication of the mineralocorticoid receptor pathway in the formation of CNV. The study (of investigators) aim is to evaluate the concentation of metabolites of MR pathway in the blood and aqueous humor of patients with CNV and compared them with patients without CNV in order to increase our understanding of CNV pathogenesis and find potential biomarker of response to anti-VEGF treatment.
Interventions
OTHERBlood and aqueous humor biomarker of treatment response
Blood analyses and aqueous humor analysis
Sponsors
Institut National de la Santé Et de la Recherche Médicale, France
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
Patients of group 1: * Patients with type 1 choroidal neovascularization in a context of central serous chorioretinoathy or age related macular degeneration * Patients without intravitreal injection or last intravitreal injection \> 3 months * Informed signed consent Patients of group 2: * Patients without choroidal neovascularization * Patients with intraocular surgery (cataract or vitrectomy surgery) * Signed consent
Exclusion criteria
* Myocardial infarction \< 12 months * Chronic renal failure * Inflammatory disease * Infectious disease :HIV, viral hepatitis, tuberculosis * Type 1 or 2 Diabetes * Patients treated by mineralocorticoid antagonist treatment. * Type 2 or 3 choroidal neovascularization * Pregnant woman
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| biomarker analysis in blood and aqueous humor of patients with neovascularization and controls | 24 months | Biomarker concentrations (pg/ml) will be evaluated with ELISA (Enzyme Linked ImmunoSorbent Assay). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| biomarkers and treatment response | 24 months | Correlation between biomarker level and the response to anti-VEGF treatment |
Countries
France
Contacts
CONTACTFrancine Behar-Cohen, Dr
Outcome results
None listed